For what it's worth: the complex area of medicine value assessment.
作者信息
Ramagopalan Sreeram V, Treharne Catrin, Pearson-Stuttard Jonathan, Subbiah Vivek
机构信息
Lane, Clark & Peacock, London, UK.
Centre for Pharmaceutical Medicine Research, King's College London, UK.
出版信息
J Comp Eff Res. 2023 Sep;12(9):e230120. doi: 10.57264/cer-2023-0120. Epub 2023 Jul 29.
Abstract
摘要
相似文献
1
For what it's worth: the complex area of medicine value assessment.不管怎样：医学价值评估的复杂领域。
J Comp Eff Res. 2023 Sep;12(9):e230120. doi: 10.57264/cer-2023-0120. Epub 2023 Jul 29.
2
Hospitals say it's not enough. Medicare payment update won't outpace inflation.医院表示这还不够。医疗保险支付的更新速度将赶不上通货膨胀。
Mod Healthc. 2005 Jul 25;35(30):8-9.
3
If it's not worth doing, it's not worth doing well.若不值得做，就不值得做好。
Pediatrics. 2005 Jan;115(1):196; author reply 196-7. doi: 10.1542/peds.2004-1971.
4
Design of a Digital Comic Creator (It's Me) to Facilitate Social Skills Training for Children With Autism Spectrum Disorder: Design Research Approach.一款数字漫画创作者（即我）的设计，用于促进自闭症谱系障碍儿童的社交技能训练：设计研究方法
JMIR Ment Health. 2020 Jul 10;7(7):e17260. doi: 10.2196/17260.
5
It's not easy being us, but it's worth it!做我们可不简单，但这值得！
Dent Today. 2002 Feb;21(2):14-7.
6
7
Look! Up in the sky! It's a bird. It's a plane. It's a medical drone!看！天空中！那是一只鸟。那是一架飞机。那是一架医疗无人机！
Lancet Haematol. 2017 Feb;4(2):e56. doi: 10.1016/S2352-3026(17)30004-2.
8
10
Access in all areas? A round up of developments in market access and health technology assessment: part 2.全覆盖？市场准入和卫生技术评估发展综述：第 2 部分。
J Comp Eff Res. 2023 Dec;12(12):e230162. doi: 10.57264/cer-2023-0162. Epub 2023 Nov 2.
引用本文的文献
1
Why is the market design for innovative pharmaceuticals not well understood?为何创新药物的市场设计未得到充分理解？
J Comp Eff Res. 2024 Oct;13(10):e240105. doi: 10.57264/cer-2024-0105. Epub 2024 Sep 10.
2
Access in all areas? A round up of developments in market access and health technology assessment: part 2.全覆盖？市场准入和卫生技术评估发展综述：第 2 部分。
J Comp Eff Res. 2023 Dec;12(12):e230162. doi: 10.57264/cer-2023-0162. Epub 2023 Nov 2.
3
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 13.我们准备好申请报销了吗？关于健康技术评估的真实世界证据进展综述：第13部分。
J Comp Eff Res. 2023 Nov;12(11):e230141. doi: 10.57264/cer-2023-0141. Epub 2023 Sep 15.
本文引用的文献
1
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in Medicare.增加了医疗保险中最畅销的品牌药物的治疗效益。
JAMA. 2023 Apr 18;329(15):1283-1289. doi: 10.1001/jama.2023.4034.
2
Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study.利用初级保健数据评估 UK 非瓣膜性心房颤动患者中阿哌沙班和利伐沙班的疗效和安全性：一项观察性队列研究。
BMJ Open. 2022 Oct 17;12(10):e064662. doi: 10.1136/bmjopen-2022-064662.
3
Progression-free survival and quality of life in metastatic breast cancer: The patient perspective.转移性乳腺癌的无进展生存期和生活质量：患者视角。
Breast. 2022 Oct;65:84-90. doi: 10.1016/j.breast.2022.07.006. Epub 2022 Jul 9.
4
Added Therapeutic Value of Medicinal Products for French and German Health Technology Assessment Organizations: A Systematic Comparison.药品治疗价值在法国和德国卫生技术评估组织中的应用：系统比较。
Value Health. 2021 Mar;24(3):346-352. doi: 10.1016/j.jval.2020.10.020. Epub 2020 Dec 1.
5
Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.欧洲司法管辖区之间的卫生技术评估建议差异：实践差异的作用。
Value Health. 2020 Jan;23(1):10-16. doi: 10.1016/j.jval.2019.07.017.
Zotero 插件